antithrombin iii

Summary

Summary: A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes; it was formerly called Antithrombin II (AT II) which has now been shown to be identical to AT III; ANTITHROMBIN III DEFICIENCY, hereditary or acquired, results in thromboembolism. It is a member of the serpin superfamily. Some authors use the term antithrombin to refer to antithrombin III.

Top Publications

  1. ncbi Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates
    Y Cadroy
    , , Toulouse, France
    Thromb Haemost 70:631-5. 1993
  2. ncbi Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study
    F Baudo
    Department of Hematology, Ospedale Niguarda, Milano, Italy
    Intensive Care Med 24:336-42. 1998
  3. ncbi Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis
    B Eisele
    Clinical Research Department, Centeon Pharma GmbH, Marburg, Germany
    Intensive Care Med 24:663-72. 1998
  4. ncbi BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
    A G G Turpie
    HHS General Hospital, Hamilton, Canada
    J Thromb Haemost 3:2479-86. 2005
  5. ncbi Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial
    B L Warren
    Brown University School of Medicine, Infectious Disease Division, Memorial Hospital of Rhode Island, 111 Brewster St, Pawtucket, RI 02860, USA
    JAMA 286:1869-78. 2001
  6. ncbi High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety
    Christian J Wiedermann
    Department of Medicine, Central Hospital of the Province of Bolzano, Bolzano, Italy
    Crit Care Med 34:285-92. 2006
  7. ncbi Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
    Dagmar Kubitza
    Clinical Pharmacology, Bayer HealthCare AG, Building 429, Aprather Weg 18a, Wuppertal, D 42096, Germany
    J Clin Pharmacol 47:218-26. 2007
  8. ncbi Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin
    Dagmar Kubitza
    Clinical Pharmacology, Bayer HealthCare AG, Wuppertal, Germany
    J Clin Pharmacol 46:981-90. 2006
  9. ncbi Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy
    H Asakawa
    Department of Endocrinology and Metabolism, Itami City Hospital, 1 100, Koyaike, Hyogo 664 8540, Itami, Japan
    J Diabetes Complications 14:121-6. 2000
  10. ncbi Inhibitory effects of antithrombin III on interactions between blood cells and endothelial cells during retinal ischemia-reperfusion injury
    Kazuaki Nishijima
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Sakyo ku, Kyoto 606 8507, Japan
    Invest Ophthalmol Vis Sci 44:332-41. 2003

Detail Information

Publications230 found, 100 shown here

  1. ncbi Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates
    Y Cadroy
    , , Toulouse, France
    Thromb Haemost 70:631-5. 1993
    The pentasaccharide (PS) comprising the minimal heparin structure capable of binding with antithrombin III (ATIII) and exhibiting anti-factor Xa (anti-fXa) activity in plasma without producing detectable antithrombin activity, has been ..
  2. ncbi Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study
    F Baudo
    Department of Hematology, Ospedale Niguarda, Milano, Italy
    Intensive Care Med 24:336-42. 1998
    ..The efficacy of ATIII therapy on mortality was assessed in a selected group of patients admitted to the intensive care unit (ICU) in a double-blind, randomized, multicenter study...
  3. ncbi Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis
    B Eisele
    Clinical Research Department, Centeon Pharma GmbH, Marburg, Germany
    Intensive Care Med 24:663-72. 1998
    To evaluate the safety and potential efficacy of antithrombin III (AT III) in reducing mortality in patients with severe sepsis.
  4. ncbi BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
    A G G Turpie
    HHS General Hospital, Hamilton, Canada
    J Thromb Haemost 3:2479-86. 2005
    ..BAY 59-7939, a novel, oral, direct factor Xa inhibitor, is in clinical development for the prevention of venous thromboembolism (VTE), a frequent complication following orthopaedic surgery...
  5. ncbi Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial
    B L Warren
    Brown University School of Medicine, Infectious Disease Division, Memorial Hospital of Rhode Island, 111 Brewster St, Pawtucket, RI 02860, USA
    JAMA 286:1869-78. 2001
    ..Diffuse microthrombus formation may induce organ dysfunction and lead to excess mortality in septic shock. Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients...
  6. ncbi High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety
    Christian J Wiedermann
    Department of Medicine, Central Hospital of the Province of Bolzano, Bolzano, Italy
    Crit Care Med 34:285-92. 2006
    To explore if patients with severe sepsis and with a predicted high risk of death (according to the Simplified Acute Physiology Score II) might have a treatment benefit from high-dose antithrombin III.
  7. ncbi Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects
    Dagmar Kubitza
    Clinical Pharmacology, Bayer HealthCare AG, Building 429, Aprather Weg 18a, Wuppertal, D 42096, Germany
    J Clin Pharmacol 47:218-26. 2007
    ..The area under the curve was unaffected by body weight or gender. No other clinically relevant differences were observed, suggesting that rivaroxaban is unlikely to require dose adjustment for body weight or gender...
  8. ncbi Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin
    Dagmar Kubitza
    Clinical Pharmacology, Bayer HealthCare AG, Wuppertal, Germany
    J Clin Pharmacol 46:981-90. 2006
    ..This study suggests that there is no clinically relevant interaction between rivaroxaban and aspirin and that the 2 drugs could be administered concomitantly at the doses used in this study...
  9. ncbi Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy
    H Asakawa
    Department of Endocrinology and Metabolism, Itami City Hospital, 1 100, Koyaike, Hyogo 664 8540, Itami, Japan
    J Diabetes Complications 14:121-6. 2000
    ..Thrombin-antithrombin III complex (TAT) and fibrinogen levels are parameters of coagulation and fibrinolysis...
  10. ncbi Inhibitory effects of antithrombin III on interactions between blood cells and endothelial cells during retinal ischemia-reperfusion injury
    Kazuaki Nishijima
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Sakyo ku, Kyoto 606 8507, Japan
    Invest Ophthalmol Vis Sci 44:332-41. 2003
    ..This study was designed to evaluate quantitatively the inhibitory effects of antithrombin (AT)-III on the interactions between blood cells and retinal endothelial cells in vivo after transient retinal ischemia...
  11. ncbi Sequence homology between human alpha 1-antichymotrypsin, alpha 1-antitrypsin, and antithrombin III
    T Chandra
    Biochemistry 22:5055-61. 1983
    ..Comparison of the amino acid sequence of alpha 1-antichymotrypsin with that of the human alpha 1-antitrypsin has revealed a homology level similar to that between chymotrypsin and trypsin...
  12. ncbi Antithrombin III pretreatment reduces neutrophil recruitment into the lung in a rat model of abdominal sepsis
    U Koca
    Department of Anesthesiology and Reanimation, Dokuz Eylul University, School of Medicine, Izmir, Turkey
    Acta Anaesthesiol Scand 49:203-8. 2005
    b>Antithrombin III (AT III) is a serine protease inhibitor and the mechanism of its anti-inflammatory action is still not understood...
  13. ncbi High-dose antithrombin III prevents heat stroke by attenuating systemic inflammation in rats
    Satoshi Hagiwara
    Department of Anesthesiology and Intensive Care Medicine, Oita University, Yufu City, Japan
    Inflamm Res 59:511-8. 2010
    ..Although anticoagulants, such as antithrombin III (AT III), inhibit inflammation resulting from various causes, their anti-inflammatory mechanism of action is ..
  14. ncbi Protective effects of recombinant human antithrombin III in pig-to-primate renal xenotransplantation
    P J Cowan
    Immunology Research Centre, St Vincent s Hospital, Melbourne, Australia
    Am J Transplant 2:520-5. 2002
    ..renal xenotransplantation model, we have tested the hypothesis that treatment with recombinant human antithrombin III would prevent or at least delay the onset of rejection and coagulopathy...
  15. ncbi Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor
    Ralf Geiben-Lynn
    Partners AIDS Research Center, Center for Immunology and Inflammatory Diseases and Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    J Biol Chem 277:42352-7. 2002
    ..Here we demonstrate that activated CD8(+) T-cells of HIV-1-seropositive individuals modify serum bovine antithrombin III into an HIV-1 inhibitory factor capable of suppressing the replication of X4 HIV-1...
  16. ncbi Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects
    Dagmar Kubitza
    Institute of Clinical Pharmacology, Bayer HealthCare AG, 42096 Wuppertal, Germany
    Eur J Clin Pharmacol 61:873-80. 2005
    ....
  17. ncbi Cerebrospinal fluid tissue factor and thrombin-antithrombin III complex as indicators of tissue injury after subarachnoid hemorrhage
    Y Hirashima
    Department of Neurosurgery, Toyama Medical and Pharmaceutical University, Japan
    Stroke 28:1666-70. 1997
    ..We hypothesized that membrane-bound tissue factor (mTF) and thrombin-antithrombin III complex (TAT) in the cerebrospinal fluid (CSF) of patients with SAH become markers indicating brain injury...
  18. ncbi Hamster antithrombin III: purification, characterization and acute phase response
    P Mak
    Institute of Molecular Biology, Jagiellonian University, Krakow, Poland
    Comp Biochem Physiol B Biochem Mol Biol 115:135-41. 1996
    b>Antithrombin III was purified to homogeneity from hamster plasma by affinity chromatography on heparin-agrose, ion-exchange chromatography on Mono Q and size-exclusion chromatography on TSK G3000SWG column with 50% yield...
  19. ncbi Factor XII but not protein C, protein S, antithrombin III, or factor XIII is a predictor of recurrent miscarriage
    M S Ogasawara
    Department of Obstetrics and Gynecology, Nagoya City University Medical School, Nagoya, Japan
    Fertil Steril 75:916-9. 2001
    OBJECTIVE: To investigate whether a decrease in the values of protein C (PC), protein S (PS), antithrombin III (ATIII), factor XII (FXII), or factor XIII (FXIII) has predictive value for subsequent miscarriages. DESIGN: Prospective study...
  20. ncbi Intravenous administration of antithrombin III induces indefinite survival of fully allogeneic cardiac grafts
    O Aramaki
    Department of Surgery, Nihon University, 30 1 Oyaguchi Kamimachi, Itabashi ku, Tokyo, Japan 173 8610
    Transplant Proc 34:1409-10. 2002
  21. ncbi The Asp(272)-Glu(282) region of platelet glycoprotein Ibalpha interacts with the heparin-binding site of alpha-thrombin and protects the enzyme from the heparin-catalyzed inhibition by antithrombin III
    R De Cristofaro
    Haemostasis Research Center, Catholic University School of Medicine, Largo F Vito, 00168 Rome, Italy
    J Biol Chem 275:3887-95. 2000
    ..fragment released by the cobra venom mocarhagin on the heparin-catalyzed rate of thrombin inhibition by antithrombin III (AT). GpIbalpha(1-282) inhibited the reaction in a dose-dependent and competitive fashion...
  22. ncbi Improved production of recombinant human antithrombin III in Chinese hamster ovary cells by ATF4 overexpression
    Tomoshi Ohya
    Advanced Medical Protein Research Laboratory, Mitsubishi Tanabe Pharma Corporation, 2 25 1 Shodai Ohtani, Hirakata, Osaka 573 1153, Japan
    Biotechnol Bioeng 100:317-24. 2008
    To improve the production of recombinant human antithrombin III (AT-III) in Chinese hamster ovary (CHO) cells, the genes encoding transcription factors, ATF4 (activating transcription factor 4) and XBP-1s (the spliced form of X-box ..
  23. ncbi A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study
    Harry R Buller
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Blood 112:2242-7. 2008
    ..8% of those receiving standard therapy. These results with simple fixed-dose oral regimens justify phase 3 evaluations (www.ClinicalTrials.gov no.NCT00395772)...
  24. ncbi Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the beta-antithrombin III isoform with enhanced heparin affinity
    V Picard
    Microbiology and Immunology Department, Temple University Medical School, Philadelphia, Pennsylvania 19140, USA
    Biochemistry 34:8433-40. 1995
    Two antithrombin III (ATIII) isoforms occur naturally in human plasma. The alpha-ATIII isoform has four N-linked oligosaccharides attached to asparagines 96, 135, 155, and 192...
  25. ncbi Effects of antithrombin III in patients with disseminated intravascular coagulation diagnosed by newly developed diagnostic criteria for critical illness
    Atsushi Sawamura
    Division of Acute and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Clin Appl Thromb Hemost 15:561-6. 2009
    A study was conducted to test the hypotheses that antithrombin III (antithrombin) improves disseminated intravascular coagulation (DIC) when applied to DIC patients diagnosed by sensitive criteria and that the administration of high-dose ..
  26. ncbi Recurrent deletion in the human antithrombin III gene
    C B Grundy
    Charter Molecular Genetics Laboratory, Thrombosis Research Institute, Chelsea, London, UK
    Blood 78:1027-32. 1991
    Eight unrelated patients with recurrent thromboembolism, a family history of thrombosis, and plasma antithrombin III (ATIII) activity/antigen levels consistent with a diagnosis of heterozygous type I ATIII deficiency were studied by ..
  27. ncbi Enzymatic synthesis of antithrombin III-binding heparan sulfate pentasaccharide
    Balagurunathan Kuberan
    Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Nat Biotechnol 21:1343-6. 2003
    ..We rapidly and efficiently assembled the antithrombin III-binding pentasaccharide in just 6 steps, in contrast to the approximately 60 steps needed for its chemical ..
  28. ncbi Impact of graded hypothermia on coagulation and fibrinolysis
    Chryssoula Staikou
    1st Department of Anesthesiology, Medical School, University of Athens, Aretaieio Hospital, Athens, Greece
    J Surg Res 167:125-30. 2011
    ..study was to investigate the effect of graded hypothermia on markers of the anticoagulant system (antithrombin III and protein C) and fibrinolytic system (plasminogen, α(2)-antiplasmin), and on vascular wall and other ..
  29. ncbi Effect of a platelet activating factor antagonist and antithrombin III on septicemia and endotoxemia in rats
    Y Inoue
    Second Department of Internal Medicine, Nagasaki University School of Medicine, Japan
    Tohoku J Exp Med 163:175-85. 1991
    ..The administration of the platelet-activating factor antagonist, CV-6209, or of human antithrombin III, ameliorated DIC significantly by limiting the increases in prothrombin time, activated partial ..
  30. ncbi Serpin receptor 1: a hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes
    S V Pizzo
    Department of Pathology and Biochemistry, Duke University Medical Center, Durham, North Carolina
    Am J Med 87:10S-14S. 1989
    b>Antithrombin III (ATIII) clearance from blood occurs by redistribution into the extravascular compartment and by binding to the endothelial surface...
  31. pmc Inhibition of HCV by the serpin antithrombin III
    Mohammed Asmal
    Division of Viral Pathogenesis, BIDMC, Boston, MA 02215, USA
    Virol J 9:226. 2012
    ..We have recently shown that ATIII, a serine protease inhibitor (serpin), has broad antiviral properties...
  32. ncbi Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III
    Genmin Lu
    Joseph Stokes Research Institute, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    J Biol Chem 279:17241-9. 2004
    ..a system reconstituted with both X and IX and the principal physiologic inhibitors of this pathway TFPI and antithrombin III (AT)...
  33. ncbi Antithrombin III activity and platelet count are more likely to decrease in twin pregnancies than in singleton pregnancies
    Tetsuo Tsunoda
    Deparetment of Obstetrics and Gynecology, Jichi Medical School, Tochigi, Japan
    Acta Obstet Gynecol Scand 81:840-5. 2002
    It is not known whether antithrombin III activity and platelet count are more likely to decrease in women with twin pregnancies than singleton pregnancies.
  34. ncbi Decrease in antithrombin III fucosylation by expressing GDP-fucose transporter siRNA in Chinese hamster ovary cells
    Takeshi Omasa
    Department of Biotechnology, Graduate School of Engineering, Osaka University, Suita, Osaka, Japan
    J Biosci Bioeng 106:168-73. 2008
    ..When synthetic small interfering RNA (siRNA) against CHO GFT was introduced into human antithrombin III (AT-III)-producing recombinant CHO cells, defucosylated AT-III increased by 30-40% after 3-d incubation...
  35. pmc Antithrombin III injection via the portal vein suppresses liver damage
    Masayuki Miyazaki
    Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812 8582, Japan
    World J Gastroenterol 18:1884-91. 2012
    To investigate the effects of antithrombin III (AT III) injection via the portal vein in acute liver failure.
  36. pmc Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis
    Christian J Wiedermann
    2nd Divison of Internal Medicine, Department of Medicine, Central Hospital of Bolzano, Bolzano, Italy
    Crit Care 10:209. 2006
    ..Final assessment of the drug's effectiveness, however, must await the availability of positive, prospective, randomized and placebo-controlled studies...
  37. ncbi Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III
    S Dunzendorfer
    Department of Internal Medicine, Innsbruck University Hospital, Innsbruck, Austria, and Aventis Behring GmbH Research, Marburg, Germany
    Blood 97:1079-85. 2001
    The serpin antithrombin III (AT III) is reported to have hemostasis-regulating and anti-inflammatory properties...
  38. ncbi Effect of ultrasound on structure and functional properties of antithrombin III and proteins of PPSB complex
    V M Shkumatov
    Research Institute of Physical Chemical Problems, Belarusian State University, Minsk 220050, Belarus
    Biochemistry (Mosc) 69:195-200. 2004
    ..4) on homogeneous antithrombin III was accompanied by formation of aggregates and a latent form of serpin...
  39. ncbi Level of antithrombin III, protein C, protein S and other selected parameters of coagulation and fibrinolysis in the blood of the patients with recurrent deep venous thrombosis
    Andrzej Swiatkiewicz
    Clinic of General Surgery, Medical University of Bydgoszcz, Poland
    Med Sci Monit 8:CR263-8. 2002
    Thrombophilia is caused mainly by disturbances of hemostasis involving excessive coagulation system activation, reduction of anticoagulation system (antithrombin III, protein C, protein S, RAPC) or fibrinolytic activity.
  40. ncbi Ostrich antithrombin III: kinetics and mechanism of inhibition of ostrich thrombin
    Carminita L Frost
    Department of Biochemistry and Microbiology, University of Port Elizabeth, P O Box 1600, South Africa
    Int J Biochem Cell Biol 34:1164-71. 2002
    ..b>Antithrombin III (ATIII) was purified from ostrich plasma by heparin-Sepharose and Super Q-650S chromatography...
  41. ncbi Familial overexpression of beta antithrombin caused by an Asn135Thr substitution
    T A Bayston
    Imperial College School of Medicine, London, UK
    Blood 93:4242-7. 1999
    ..This case represents a novel cause of antithrombin deficiency, removal of glycosylation concensus sequence, and highlights the potentially important role of beta antithrombin in regulating coagulation...
  42. ncbi The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions
    H A Schreuder
    BIOSON Research Institute, University of Groningen, Nijenborgh, The Netherlands
    Nat Struct Biol 1:48-54. 1994
    ..The intact reactive site loop is in a novel conformation that seems well suited for interaction with proteinases such as thrombin and blood coagulation factor Xa...
  43. ncbi Molecular cloning and cell-free expression of mouse antithrombin III
    J K Wu
    Canadian Red Cross Society Blood Transfusion Service, McMaster University, Hamilton, Ontario
    Thromb Haemost 68:291-6. 1992
    The homology between antithrombin III (AT-III) of mouse, of man, and that of other species was investigated. Preliminary experiments showed that mouse AT-III inhibited human alpha-thrombin efficiently (second order rate constant [K2nd] 5...
  44. ncbi Comparison of general and spinal anesthesia and their influence on hemostatic markers in patients undergoing total hip arthroplasty
    Sabine Brueckner
    Department of Anesthesiology, Department of Internal Medicine, Subdivision of Hemostaseology, University of Luebeck, Ratzeburger Allee 160, D 23528 Luebeck, Germany
    J Clin Anesth 15:433-40. 2003
    ..To evaluate the profile of molecular hemostatic markers in patients receiving either spinal or balanced general anesthesia for total hip arthroplasty...
  45. ncbi Dose response of intravenous heparin on markers of thrombosis during primary total hip replacement
    N E Sharrock
    Department of Anesthesiology, The Hospital for Special Surgery, Cornell University Medical College, New York, New York 10021, USA
    Anesthesiology 90:981-7. 1999
    ..This study assesses the effect of two doses of unfractionated intravenous heparin administered before femoral preparation during THR on circulating markers of thrombosis...
  46. ncbi Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation
    J Kienast
    Department of Internal Medicine, Hematology Oncology, Westfaelische Wilhelms University, Muenster, Germany
    J Thromb Haemost 4:90-7. 2006
    ..Disseminated intravascular coagulation (DIC) is a serious complication of sepsis that is associated with a high mortality...
  47. pmc The anticoagulant activation of antithrombin by heparin
    L Jin
    Department of Haematology, University of Cambridge, Hills Road, Cambridge CB2 2QH, United Kingdom
    Proc Natl Acad Sci U S A 94:14683-8. 1997
    ..This clear definition of the binding site will provide a structural basis for developing heparin analogues that are more specific toward their intended target antithrombin and therefore less likely to exhibit side effects...
  48. ncbi Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients
    Demetrios J Kutsogiannis
    Division of Critical Care Medicine, Department of Public Health Sciences, The University of Alberta, Edmonton, Alberta, Canada
    Kidney Int 67:2361-7. 2005
    ....
  49. ncbi AIDS and thrombosis: retrospective study of 131 HIV-infected patients
    M W Saif
    National Cancer Institute, National Institute of Health, Bethesda, Maryland 20889, USA
    AIDS Patient Care STDS 15:311-20. 2001
    ....
  50. ncbi Anti-viral activity of human antithrombin III
    David R Elmaleh
    Division of Nuclear Medicine and Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Mol Med 16:191-200. 2005
    ..CD8+ T-cell-modified antithrombin III (ATIII) accounts for some of the described CD8+ T-cell anti-viral activity...
  51. ncbi Structural view of glycosaminoglycan-protein interactions
    Anne Imberty
    CERMAV CNRS affiliated with Université Joseph Fourier, BP 53, F 38041 Grenoble, France
    Carbohydr Res 342:430-9. 2007
    ..The example of interactions between heparin and antithrombin III illustrates how such a complex mechanism as the regulation of blood coagulation by a specific pentasaccharide ..
  52. ncbi High dose of antithrombin III induces indefinite survival of fully allogeneic cardiac grafts and generates regulatory cells
    Osamu Aramaki
    Department of Surgery, Nihon University, Tokyo, Japan
    Transplantation 75:217-20. 2003
    The authors investigated whether antithrombin III (AT-III) could induce unresponsiveness to alloantigens.
  53. ncbi Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass
    M S Avidan
    Department of Anesthesiology and Cardiothoracic Surgery, Washington University School of Medicine, 660 South Euclid, St Louis, MO 63110, USA
    J Thorac Cardiovasc Surg 130:107-13. 2005
    We sought to evaluate the efficacy of recombinant human antithrombin III for restoration of heparin responsiveness in heparin-resistant patients scheduled for cardiac surgery.
  54. ncbi Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery
    John H Lemmer
    Northwest Surgical Associates, Portland, OR 97210, USA
    J Thorac Cardiovasc Surg 123:213-7. 2002
    The purpose of this report is to describe the clinical use of antithrombin III concentrate in 53 patients who were found, in the operating room before cardiopulmonary bypass, to be heparin resistant.
  55. ncbi Reduction of ischemia/reperfusion injury by antithrombin III after experimental pancreas transplantation
    Thilo Hackert
    Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
    Am J Surg 189:92-7. 2005
    Graft pancreatitis is a major complication after pancreas transplantation. Antithrombin III (AT III) is an anticoagulatory and anti-inflammatory substance...
  56. ncbi Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production
    Akio Mizutani
    Intensive Care Unit, Oita Medical University, Japan
    Blood 101:3029-36. 2003
    ..The therapeutic effects of AT might be mainly mediated by PGI(2) released from endothelial cells through interaction of AT with cell surface glycosaminoglycans...
  57. ncbi Immunocytochemical localization of endogenous anti-thrombin III in the vasculature of rat tissues reveals locations of anticoagulantly active heparan sulfate proteoglycans
    Y Xu
    Laboratory of Electron Microscopy, Dana Farber Cancer Institute, Boston, Massachusetts 02115
    J Histochem Cytochem 42:1365-76. 1994
    ....
  58. ncbi Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism
    Hirofumi Kawanaka
    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Ann Surg 251:76-83. 2010
    The aim of this study was to determine the role of antithrombin III (AT-III) in portal vein thrombosis (PVT) after splenectomy in cirrhotic patients.
  59. ncbi A case of acute myocardial infarction with repetitive stent thrombosis during emergent percutaneous coronary intervention. Transient decrease in antithrombin III activity and heparin resistance
    Bunji Kaku
    Division of Cardiovascular Medicine, Toyama Red Cross Hospital, Toyama, Japan
    Int Heart J 50:111-9. 2009
    ..In the acute phase, a decrease in the antithrombin III activity (65%) was noted and with administration of argatroban, prolongation of the aPTT was achieved...
  60. ncbi The serine protease inhibitor antithrombin III inhibits LPS-mediated NF-kappaB activation by TLR-4
    A Mansell
    Department of Biochemistry, Trinity College Dublin, Ireland
    FEBS Lett 508:313-7. 2001
    ..The serpin antithrombin III (ATIII) and the thrombin inhibitor hirudin both inhibited nuclear factor (NF)-kappaB activation by LPS and ..
  61. ncbi Enzymatic modification of heparan sulfate on a biochip promotes its interaction with antithrombin III
    M Hernaiz
    Division of Medicinal and Natural Products Chemistry, University of Iowa, Iowa City, Iowa, 52242, USA
    Biochem Biophys Res Commun 276:292-7. 2000
    ..Surface plasmon resonance spectroscopy showed a low affinity interaction with antithrombin III (ATIII) when it was flowed over a surface containing heparan sulfate...
  62. ncbi Antithrombin III pretreatment reduces neutrophil recruitment into the lung and skeletal muscle tissues in the rat model of bilateral lower limb ischemia and reperfusion: a pilot study
    S Duru
    Department of Anesthesiology and Reanimation, Ataturk Training and Research Hospital, Dokuz Eylul University, School of Medicine, Izmir, Turkey
    Acta Anaesthesiol Scand 49:1142-8. 2005
    Anti-inflammatory action of Antithrombin III (AT III) is still not well understood in ischemia/reperfusion (I/R) injury...
  63. ncbi Antithrombin III attenuates pulmonary tissue injury caused by mesenteric ischemia-reperfusion
    Faruk O Aytekin
    Department of General Surgery, Pamukkale University, Medical School, Denizli, Turkey
    Am J Surg 189:161-6. 2005
    ..Here, we examined the effects of antithrombin on pulmonary injury after mesenteric I/R...
  64. ncbi Activated cytotoxic T cells and NK cells in severe sepsis and septic shock and their role in multiple organ dysfunction
    Sacha Zeerleder
    Central Hematology Laboratory, Inselspital, Bern, Switzerland
    Clin Immunol 116:158-65. 2005
    ..Activated cytotoxic cells reflected by elevated granzymes A and/or B were found in 50% of our sepsis patients. This group showed a higher mortality and a worse organ function...
  65. ncbi Enzymatic preparation of heparin oligosaccharides containing antithrombin III binding sites
    T Toida
    Division of Medicinal and Natural Products Chemistry, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, USA
    J Biol Chem 271:32040-7. 1996
    ..2.2.7) in an attempt to prepare oligosaccharides having intact antithrombin III binding sites...
  66. ncbi Elimination of P1 arginine 393 interaction with underlying glutamic acid 255 partially activates antithrombin III for thrombin inhibition but not factor Xa inhibition
    Mohamad Aman Jairajpuri
    Department of Medicine, University of Utah, Salt Lake City, Utah 84132, USA
    J Biol Chem 277:24460-5. 2002
    The mechanism for heparin activation of antithrombin III has been postulated to involve disruption of interactions between its reactive loop P1 residue and Glu(255) on the underlying protein surface...
  67. ncbi Contribution of capsaicin-sensitive sensory neurons to antithrombin-induced reduction of ischemia/reperfusion-induced liver injury in rats
    Naoaki Harada
    Department of Diagnostic Medicine, Graduate School of Medical Sciences, Kumamoto University, Honjo 1 1 1, Kumamoto 860 0811, Japan
    Thromb Haemost 93:48-56. 2005
    ..In this process, CGRP-induced activation of both endothelial nitric oxide synthase and cyclooxygenase-1 might be critically involved...
  68. ncbi Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms
    Johannes N Hoffmann
    Department of Surgery, Chirurgische Klinik, Klinikum Grosshadern, Ludwig Maximilians Universitat, Marchioninistr 15, D 81377 Munchen, Germany
    Thromb Haemost 88:242-52. 2002
    ..These results indicate that heparin should be avoided to permit AT to modulate LPS-induced inflammatory responses...
  69. pmc Cloning and expression of the cDNA for human antithrombin III
    S C Bock
    Nucleic Acids Res 10:8113-25. 1982
    A partial cDNA clone for human antithrombin III (ATIII) was obtained by screening a cDNA library prepared from size fractionated liver RNA with a pool of eight 16-base long synthetic DNA fragments whose sequence was determined from ..
  70. ncbi Plasma antithrombin III and protein C levels in early recognition of late-onset sepsis in newborns
    Ryszard Lauterbach
    Department of Neonatology, Jagiellonian University Medical College, Kopernika 23, 31 501 Cracow, Poland
    Eur J Pediatr 165:585-9. 2006
    The aim of this prospective, observational study was to establish the prognostic values of plasma antithrombin III (ATIII) and protein C (PC) functional levels, determined in 150 neonates with suspected late-onset sepsis.
  71. pmc Characterization of heparin oligosaccharides binding specifically to antithrombin III using mass spectrometry
    Hicham Naimy
    Department of Biochemistry, Boston University School of Medicine, 670 Albany Street, Boston, Massachusetts 02118, USA
    Biochemistry 47:3155-61. 2008
    ..we describe a hydrophobic trapping assay for screening a library of heparin hexasaccharides for binders to antithrombin III (ATIII)...
  72. ncbi Latex immunoturbidimetric assay for soluble fibrin complex
    Akiei Hamano
    Central Research Laboratory of Nissui Pharmaceutical Co, Ltd, Ibaraki 307 0036, Japan
    Clin Chem 51:183-8. 2005
    ..Its detection and quantification are useful for obtaining information about the condition and degree of intravascular coagulation in early-stage thrombosis, but there is no rapid method to measure SFC in plasma for clinical use...
  73. ncbi Antithrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and its conformational activation
    Mohamad Aman Jairajpuri
    Departments of Medicine and Bioengineering, Health Science Center, University of Utah, 50 N Medical Drive, Salt Lake City, UT 84132, USA
    J Biol Chem 278:15941-50. 2003
    The dissociation equilibrium constant for heparin binding to antithrombin III (ATIII) is a measure of the cofactor's binding to and activation of the proteinase inhibitor, and its salt dependence indicates that ionic and non-ionic ..
  74. ncbi Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill patients with suspected sepsis
    Ville Pettila
    Intensive Care Unit, Department of Anaesthesiology and Intensive Care Medicine, Helsinki University Hospital, Helsinki, Finland
    Crit Care Med 30:271-5. 2002
    To evaluate at admission the performance of serum antithrombin III, serum C-reactive protein, white blood cell and platelet counts, and thromboplastin time values in prediction of hospital mortality rates in critically ill patients with ..
  75. ncbi High antithrombin III levels attenuate hemostatic activation and leukocyte activation during cardiopulmonary bypass
    Andreas Koster
    Department of Anesthesia, Deutsches Herzzentrum Berlin, Augustenburgerplatz 1, D 13353 Berlin, Germany
    J Thorac Cardiovasc Surg 126:906-7. 2003
  76. ncbi Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy
    K Wickstrom
    Department of Obstetrics and Gynecology, Karolinska Institute at Stockholm Söder Hospital, Stockholm, Sweden
    Scand J Clin Lab Invest 64:31-40. 2004
    ..Clearly, current reference values based on healthy non-pregnant subjects are not usable during late pregnancy and immediately postpartum...
  77. doi Reduced levels of fibrin (antithrombin I) and antithrombin III underlie coagulopathy following complex cardiac surgery
    Roman M Sniecinski
    Blood Coagul Fibrinolysis 19:178-9. 2008
  78. ncbi Roles of protein C, protein S, and antithrombin III in acute leukemia
    Ashish Dixit
    Department of Hematology, All India Institute of Medical Sciences, New Delhi, India
    Am J Hematol 81:171-4. 2006
    Protein C, protein S, and antithrombin III were measured in 35 patients with acute leukemia (13 with AML and 22 with ALL). Low levels of proteins C and S were present in 15 (42.9%) and 20 (57...
  79. ncbi Coagulation inhibitors in preeclamptic pregnant women
    Mehmet A Osmanagaoglu
    Department of Obstetrics and Gynecology, Faculty of Medicine, Karadeniz Technical University, 61080 Trabzon, Turkey
    Arch Gynecol Obstet 271:227-30. 2005
    ..Our objective was to detect clinical evaluation of coagulation inhibitors in preeclamptic and normotensive pregnant women and to determine their important role in pathogenesis of preeclampsia...
  80. ncbi A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
    Maurice Petitou
    Département Cardiovasculaire Thrombose, Sanofi Synthelabo, 195 route d Espagne, 31036 Toulouse Cedex, France
    Angew Chem Int Ed Engl 43:3118-33. 2004
    ..In the early 1980s it was discovered that a unique pentasaccharide domain in some heparin chains activates antithrombin III (AT-III), a serine protease inhibitor that blocks thrombin and factor Xa in the coagulation cascade...
  81. ncbi Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome?
    S C Koh
    National University of Singapore, Department of Obstetrics and Gynaecology, National University Hospital, Singapore
    Clin Appl Thromb Hemost 7:141-8. 2001
    ..Enhanced thrombin generation, evidenced by increased F1+2 and decreased antithrombin III (ATIII) levels with further enhanced fibrinolysis by elevated D-dimer, was seen in advanced cancer...
  82. ncbi Haemostatic changes; plasma levels of alpha2-antiplasmin-plasmin complex and thrombin-antithrombin III complex in female breast cancer
    O Ozyilkan
    Bayindir Tip Merkezi, Medical Center, Department of Internal Medicine, Ankara, Turkey
    Tumori 84:364-7. 1998
    ..the fibrinolytic system marker alpha2-antiplasmin-plasmin complex (APP) and clotting system marker thrombin-antithrombin III complex (TAT) in patients with breast cancer and compare them with CA 15-3, the most well-known breast cancer ..
  83. ncbi Uncoupling of protein C and antithrombin III activity in cerebral ischemia patients associated with cutis marmorata
    Tzu Hui Li
    Department of Neurology, Chang Gung Memorial Hospital Kaohsiung Medical Center, and School of Medicine, Chang Gung University, Kaohsiung, Taiwan
    Acta Neurol Taiwan 17:233-8. 2008
    ..Unlike Sneddon syndrome, a detailed immunocoagulation profile has not yet been delineated for cutis marmorata in patients with cerebral ischemia...
  84. ncbi Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by a template mechanism. Evidence that calcium alleviates Gla domain antagonism of heparin binding to factor Xa
    A R Rezaie
    Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA
    J Biol Chem 273:16824-7. 1998
    ....
  85. ncbi Influence of antithrombin III on coagulation and inflammation in porcine septic shock
    G Dickneite
    Centeon Pharma GmbH, 35002 Marburg Medical Clinic, Justus Liebig University, 35385 Giebetaen, Germany
    Arterioscler Thromb Vasc Biol 19:1566-72. 1999
    The physiological inhibitor of thrombin, antithrombin III (ATIII, Kybernin P) was investigated for its antiinflammatory and anticoagulant effects in a pig model of septic shock. Pigs were infused with a dose of 0.25 microgram. kg-1...
  86. ncbi Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells
    Christian Oelschläger
    Division of Cardiology, Department of Internal Medicine, University of Giessen, Germany
    Blood 99:4015-20. 2002
    The serpin antithrombin III (AT III), the most important natural inhibitor of thrombin activity, has been shown to exert marked anti-inflammatory properties and proven to be efficacious in experimental models of sepsis, septic shock, and ..
  87. ncbi Activated protein C resistance in Turkish women with severe preeclampsia
    M Cetin
    Department of Internal Medicine, Division of Hematology, Erciyes University Medical School, Kayseri, Turkey
    Gynecol Obstet Invest 52:168-72. 2001
    ..05). Our results indicate that acquired APC-R may be a contributory factor in the pathogenesis of preeclampsia...
  88. ncbi Haemodilution-induced enhancement of coagulation is attenuated in vitro by restoring antithrombin III to pre-dilution concentrations
    T G Ruttmann
    Department of Anaesthesia and Haematology, University of Cape Town, South Africa
    Anaesth Intensive Care 29:489-93. 2001
    ..an in vitro study to determine whether the effect can be moderated or prevented when the reduction in antithrombin III caused by dilution is prevented by supplementation. Blood from 20 volunteers was divided into four samples...
  89. ncbi Autoantibody against prothrombin aberrantly alters the proenzyme to facilitate formation of a complex with its physiological inhibitor antithrombin III without thrombin conversion
    S Madoiwa
    Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical School, Minamikawachi-machi, Tochigi 329-0498, Japan
    Blood 97:3783-9. 2001
    ..The antibody-bound prothrombin formed a stable stoichiometric complex with antithrombin III, consisting of intact prothrombin and an antithrombin III molecule cleaved at the (393)Arg-(394)Ser bond...
  90. pmc Complete antithrombin deficiency in mice results in embryonic lethality
    K Ishiguro
    First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan
    J Clin Invest 106:873-8. 2000
    ..These findings suggest that antithrombin is essential for embryonic survival and that it plays an important role in regulation of blood coagulation in the myocardium and liver...
  91. pmc Antithrombin III in critically ill patients
    A Torossian
    BMJ 335:1219-20. 2007
  92. ncbi High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats
    Satoshi Hagiwara
    Oita University Faculty of Medicine, Department of Brain and Nerve Science, Anesthesiology, 1 1 Idaigaoka, Hasamamachi, Yufu City, Oita 879 5593, Japan
    Intensive Care Med 34:361-7. 2008
    High mobility group box 1 (HMGB1) is an important factor in the development of sepsis. Previous work suggests that antithrombin III (ATIII) inhibits inflammation, but the mechanism of action is still poorly understood.
  93. ncbi Natural anticoagulants (antithrombin III, protein C, and protein S) in patients with mild to moderate ischemic stroke
    E Haapaniemi
    Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland
    Acta Neurol Scand 105:107-14. 2002
    The role of the natural anticoagulants, antithrombin III (AT III), protein C (PC), and protein S (PS), in patients with mild to moderate ischemic stroke remains uncertain...
  94. ncbi Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli
    M C Minnema
    Sanquin Blood Supply Foundation, Amsterdam, The Netherlands the Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands
    Blood 95:1117-23. 2000
    Plasma-derived antithrombin III (ATIII) prevents the lethal effects of Escherichia coli infusion in baboons, but the mechanisms behind this effect are not clear...
  95. ncbi The role of antithrombin III in critical patients in obstetrics
    S Mangione
    Department of Anesthesiology, Intensive Care and Emergency, University of Palermo, Italy
    Minerva Anestesiol 68:449-53. 2002
    ..Inflammatory cytokines (IL 6, TNF, IL 10), Antithrombin III (AT III), Protein C (PC) and Tissue Factor Pathway Inhibitor (TFPI) plasma level and Organ Disfunction ..
  96. pmc Conformational transitions induced in heparin octasaccharides by binding with antithrombin III
    Marco Guerrini
    G Ronzoni Institute for Chemical and Biochemical Research, Via G Colombo 81, 20133 Milan, Italy
    Biochem J 399:191-8. 2006
    ..Thus, for each AT binding sequence longer than AGA*IA, the interactions with the protein could differ and give to each heparin fragment a specific biological response...
  97. ncbi The antithrombin III-saving effect of reduced systemic heparinization and heparin-coated circuits
    Marco Ranucci
    Departments of Cardiothoracic Anesthesia and Cardiac Surgery, Cardiovascular Center E Malan University of Milan, Istituto Policlinico S Donato, Milan, Italy
    J Cardiothorac Vasc Anesth 16:316-20. 2002
    To investigate the perioperative changes of antithrombin III (AT-III) activity using reduced systemic heparinization and the possible role of AT-III in determining a better postoperative outcome.
  98. pmc Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis
    Arash Afshari
    Department of Anaesthesiology, Rigshospitalet, Juliane Marie Centre, University of Copenhagen, Copenhagen, Denmark
    BMJ 335:1248-51. 2007
    To evaluate the benefits and harms of antithrombin III in critically ill patients.
  99. ncbi Inhibitory effects of antithrombin III against leukocyte rolling and infiltration during endotoxin-induced uveitis in rats
    K Yamashiro
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Japan. Department of Ophthalmology, Nagoya City University Medical School, Japan
    Invest Ophthalmol Vis Sci 42:1553-60. 2001
    ..The current findings suggest that ATIII may have a role in the management of patients with uveitis...
  100. pmc Hyperproduction of fibrin and inefficacy of antithrombin III and alpha2 macroglobulin in the presence of bacterial porins
    Biagio Di Micco
    Clinical Chemistry, University of Sannio, Benevento, Italy
    Int J Exp Pathol 86:241-5. 2005
    ..Also, fibrin hyperproduction took place even in the presence of the thrombin inhibitors antithrombin III (AT III) or alpha2 macroglobulin (alpha2M)...
  101. ncbi Characterization of antithrombin III from human plasma by two-dimensional gel electrophoresis and capillary electrophoretic methods
    Leopold Kremser
    Institute of Analytical Chemistry, University of Vienna, Vienna, Austria
    Electrophoresis 24:4282-90. 2003
    The isoforms distribution of the glycoprotein antithrombin III (ATIII) derived from human plasma was investigated by means of isoelectric focusing (IEF) in polyacrylamide gels with immobilized pH gradients (IPG) and two-dimensional gel ..

Research Grants62

  1. SEQUENCING THE POLYSACCHARIDE COMPONENT OF PROTEOGLYCANS
    Robert J Linhardt; Fiscal Year: 2012
    ..An unusual GlcN2S3S6S residue found within heparin, also marks the center of its binding site for antithrombin III. Two unusual residues, GlcN3S6S and GlcA2S, in the heparan sulfate (HS) receptor responsible for herpes ..
  2. Sex Differences in Vascular Markers of Stroke Risk
    Cheryl D Bushnell; Fiscal Year: 2012
    ..MMP-9), vascular cell adhesion molecule-1 (VCAM-1), von Willebrand Factor (vWF), and thrombin-antithrombin III complex (TAT)...
  3. Identifying novel genetic risk factors for venous thromboembolism (VTE)
    Jun Li; Fiscal Year: 2013
    ..this cohort to other potential modifiers of thrombosis risk such as FV, FVIII, plasminogen, PAI-1, D-dimer, antithrombin III, Protein S, and Protein C...
  4. SYNTHESIS AND TESTING OF A NEW CLASS OF HEPARINOIDS
    Joseph Toce; Fiscal Year: 1991
    ..Dr. Tollefsen, one of the consultants, will examine the effects of active compounds on the rate of thrombin inhibition by purified antithrombin III and heparin cofactor II as established in his laboratory.
  5. Beta Cell Regeneration by Reprogramming of Adult Pancreatic Cells
    Pedro L Herrera; Fiscal Year: 2013
    ....
  6. ENVIRONMENTAL MODULATION OF FIBRINOLYSIS INHIBITORS
    STEVEN GONIAS; Fiscal Year: 1992
    ..The function of a2AP, a2- macmacroglobulin (a2M), and antithrombin III (AT) will be evaluated...
  7. Libman-Sacks Endocarditis and NPSLE
    Carlos Roldan; Fiscal Year: 2009
    ..2, thrombin-antithrombin III complexes, and platelet aggregation;and 7) cranial MRI, diffusion weighted imaging and perfusion weighted ..
  8. The Molecular Pathogenesis of Hookworm Anemia
    Michael Cappello; Fiscal Year: 2005
    ..These studies will ultimately determine the role of blood feeding in the pathogenesis of hookworm disease, as well as identify potential targets for a human vaccine against this globally important parasite. ..
  9. The Molecular Pathogenesis of Hookworm Anemia
    Michael Cappello; Fiscal Year: 2001
    ..These studies will ultimately determine the role of blood feeding in the pathogenesis of hookworm disease, as well as identify potential targets for a human vaccine against this globally important parasite. ..
  10. Biomedical Polymers With Heparin-Binding End Groups
    Robert Ward; Fiscal Year: 2004
    ..A biological assay that measures the amount of antithrombin III (ATIII) that binds to the heparinized surface will also be used to determine if the adsorbed heparin ..
  11. NMR STRUCTURES OF PLATELET FACTOR 4 & B-THROMBOGLOBULIN
    Kevin Mayo; Fiscal Year: 1992
    ..PF4 is known to strongly bind heparin thereby inhibiting the formation of thrombin-antithrombin III complexes at vascular sites...
  12. GENETIC ANALYSIS OF CHARCOT-MARIE-TOOTH DISEASE
    PHILLIP CHANCE; Fiscal Year: 1992
    ..with known gene markers from chromosome 1 including: alpha actin, alpha spectrin, amylase, amyloid P, antithrombin III, apolipoprotein AII, H4 histone, N-ras, C-reactive protein and p308...
  13. CELLULAR INTERACTIONS OF PLASMA PROTEINS
    Peter Walsh; Fiscal Year: 2001
    ..Serpins) will focus on the structure-activity relationships with a naturally occurring anticoagulant serpin, antithrombin III, and will aim to develop recombinant serpins which are targeted tot he vessel wall to block the actions of ..
  14. A Novel Family of Anticoagulants from Ixodes scapularis
    Michel Ledizet; Fiscal Year: 2003
    ..These studies will relate structure and function, and provide a rational basis for selecting anticoagulant molecules for Phase II animal studies. ..
  15. TRANSCRIPTIONAL ACTIVATION BY TRANSCRIPTION COFACTOR-1
    PAUL KHAVARI; Fiscal Year: 1992
    ..These genes include those encoding coagulation factors such as fibrinogen, antithrombotic factors such as antithrombin III and protein C as well as those involved in cholesterol metabolism...
  16. MOLECULAR BIOLOGY AND PHYSIOLOGY OF HUMAN FACTOR VII
    Steven Idell; Fiscal Year: 1992
    ..Factor VIIa may also be inhibited by antithrombin III in the presence of heparin...
  17. STRUCTURAL STUDIES ON HEPARIN-BINDING PROTEINS
    PETER GETTINS; Fiscal Year: 1991
    ..i) Heparin is extensively used as an anticoagulant. It expresses this activity through interaction with antithrombin III, an inhibitor of several blood clotting proteins...
  18. Non-anticoagulant ODS Heparin in Myocardial Infarction
    ALAN CARDIN; Fiscal Year: 2002
    ..lyophilization that selectively and quantitatively removes the 2-O and 3- O sulfates necessary for binding antithrombin III, critical for heparin's anti-coagulant effect...
  19. DNA CRUCIFORMS AND HUMAN DISEASE
    John Bissler; Fiscal Year: 1999
    ..This region forms a thermodynamically stable stem loop structure. Similar structures are found in the Antithrombin III (ATIII) human immunodeficiency virus TAR and platelet drive growth factor A genes...
  20. NON-RESPONDERS FOLLOWING VENOUS OCCLUSION
    Karol Lacroix; Fiscal Year: 1991
    ..with excessive or uncontrolled clotting, decreased levels of naturally occurring inhibitors such as antithrombin III and Protein C, or hypofibrinolysis...
  21. HEPARIN ACTIVATION OF ANTITHROMBIN III
    Susan Bock; Fiscal Year: 1999
    ..an anticoagulant, the actual mechanism by which heparin dramatically increases the anticoagulant activity of antithrombin III is not well understood...
  22. Novel Approaches to the Inhibition of Anthrax Toxin
    ANDREW ARTENSTEIN; Fiscal Year: 2003
    ....
  23. TRANSCRIPTIONAL REGULATION OF ENDOTHELIAL CELL FUNCTIONS
    CORA JEAN EDGELL; Fiscal Year: 1991
    ..cells include not only thrombogenic agents like von Willebrand factor, but also antithrombogenic agents like antithrombin III, and fibrinolytic agents like tissue plasminogen activator...
  24. MOLECULAR BASIS OF BLOOD COAGULATION REGULATION
    Steven Olson; Fiscal Year: 1992
    ..ions and GAG- binding proteins is modulating the rate of neutralization of blood coagulation-proteases by antithrombin III and other inhibitors will be investigated by rapid kinetic and equilibrium binding studies...
  25. GENE TRANSFER IN MODELS OF ARTERIAL INJURY
    Robert Simari; Fiscal Year: 2000
    ....
  26. OU Developmental Center for Injury Prevention Research
    Gary Raskob; Fiscal Year: 2005
    ..abstract_text> ..
  27. OU Human Research Protection Program, Year 2
    Gary Raskob; Fiscal Year: 2003
    ..The University of Oklahoma is committed to maintaining these initiatives after the term of this award. ..
  28. MOLECULAR BASIS OF COAGULATION PROTEASE SPECIFICITY
    Alireza R Rezaie; Fiscal Year: 2010
    ....
  29. PHARMACOGENETICS IN SURGICAL CRITICAL CARE
    Bradley Freeman; Fiscal Year: 2004
    ..The environment for this project is Washington University School of Medicine, an institution with access to a large clinical volume and established expertise in genomic research. ..
  30. Fat Induced Insulin Resistance and Atherosclerosis
    Guenther Boden; Fiscal Year: 2007
    ..We believe that these studies will provide important new information relative to the mechanism by which obesity and FFAs cause IR and ASVD in human subjects. ..
  31. Structural examination of serpin-protein interactions
    PETER GETTINS; Fiscal Year: 2009
    ..Dudley Strickland. ..
  32. Growth Factors in Vascular Biology
    MATTHEW NUGENT; Fiscal Year: 2008
    ..These studies will have wide ranging impact on vascular biology and will likely reveal previously undefined mechanisms of growth factor control that could help identify targets for clinical modulation. ..
  33. Free Fatty Acids and Hepatic Insulin Resistance
    Guenther Boden; Fiscal Year: 2007
    ..These studies will hopefully provide much needed information relative to important details and mechanisms of FFA induced hepatic insulin resistance. [unreadable] [unreadable]..
  34. Vein wall remodeling after DVT is matrix metalloproteinase dependent
    Peter Henke; Fiscal Year: 2009
    ..This proposal will provide important mechanistic insight into the pathophysiology of post-phelbitic syndrome with real potential translation to decreasing the morbidity from this under-acknowledged disease. ..
  35. Pathogenesis of Thrombosis in HIT/T
    Michael Reilly; Fiscal Year: 2009
    ..This new information may facilitate development of improved diagnostic tests and therapy for patients at risk for heparin-induced life-threatening thrombosis. ..
  36. Machine Learning to Identify Complex Interactions in Genome-Wide Association Data
    David Herrington; Fiscal Year: 2009
    ..Determining specific genetic and/or environmental factors that influence a person's risk of disease may help doctors reduce risk for disease and reveal new treatments for disease. (End of Abstract) ..
  37. PROSPECTIVE INVESTIGATION OF PULMONARY EMBOLISM DX-II
    Victor Tapson; Fiscal Year: 2003
    ..abstract_text> ..
  38. An Artificial Golgi: Controlled GAG Synthesis and Screening
    ROBERT J contact LINHARDT; Fiscal Year: 2010
    ..This artificial Golgi uses a digital microfluidic platform for synthesis and screen activity on a cell microarray to develop a structure activity relationship for fibroblast growth factor signaling. ..
  39. Normobaric Hyperoxia in Acute Ischemic Stroke
    Aneesh B Singhal; Fiscal Year: 2010
    ..Breathing high-flow oxygen may prove to be a simple, practical, portable, and potentially cost-effective therapy that improves stroke outcomes, either independently or by extending the time window for IV tPA. ..
  40. FUNCTION AND DYSFUNCTION IN HUMAN ANTITHROMBINS
    PETER GETTINS; Fiscal Year: 2007
    ..For antithrombins that have been activated by mutation,[unreadable] x-ray crystallography, through collaboration with Dr. Robin Carrell,[unreadable] will be used.[unreadable]..
  41. FGF-Silyl-Heparin Cerebral Aneurysm Coils
    PAUL ZAMORA; Fiscal Year: 2002
    ..The Phase I studies will develop the coated coils and perform initial animal evaluations. ..
  42. IGFBP5 AND INTEGRINS AND CONTROLLING IGF1 ACTIONS
    David Clemmons; Fiscal Year: 2002
    ....
  43. PATHOGENIC MECHANISMS AND INTERVENTION STRATEGIES IN HUS
    Richard Siegler; Fiscal Year: 2002
    ....
  44. Estrogen regulation of osteoclastogenesis in older men
    Pamela Taxel; Fiscal Year: 2003
    ..abstract_text> ..
  45. Thrombosis Gene Polymorphisms and Early CHD Risk in HERS
    David Herrington; Fiscal Year: 2004
    ....
  46. Acquisition of an electrospray TOF mass spectrometer
    IGOR KALTASHOV; Fiscal Year: 2004
    ..The operation of the instrument will be overseen by a Mass Spectrometry Advisory committee comprised of faculty members representing three academic departments and one interdisciplinary research center at UMass. ..
  47. Treatment of Hyperglycemia Ischemic Stroke(THIS)Trial
    Askiel Bruno; Fiscal Year: 2004
    ..Additional measurements will include vital signs, serum electrolytes, hemoglobin A-1C, and a global test for multiple clinical outcomes at 3 months. ..
  48. Immune Mechanisms in Heparin-Induced Thrombocytopenia/T*
    Michael Reilly; Fiscal Year: 2004
    ....
  49. Thromboresistant vascular grafts:heparin-peptidomimetics
    PAUL ZAMORA; Fiscal Year: 2004
    ..abstract_text> ..
  50. Estrogen Receptor Variance and CHD Risk in HERS
    David Herrington; Fiscal Year: 2004
    ..In addition, this information could lead to fundamentally important new knowledge about mechanisms of estrogen action, regulation of HDL cholesterol, and pathogenesis of CHD. ..
  51. Glycosaminoglycan-Protein Interactions
    Robert Linhardt; Fiscal Year: 2003
    ....
  52. Thrombus resolution is CXC chemokine dependent
    Peter Henke; Fiscal Year: 2006
    ..abstract_text> ..
  53. ACQUISITION OF CRYOPROBE FOR 600 MHZ NMR SPECTROMETER
    PETER GETTINS; Fiscal Year: 2001
    ..Olson, with interests in serpin inhibition mechanism, Dr. Patston, with interests in the structure of the serpin angiotensinogen, and Dr. Silver, who is characterizing a unique silver binding protein, silE. ..